Cantor Fitzgerald Maintains Overweight on Novo Nordisk, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen maintains an Overweight rating on Novo Nordisk (NVO) and raises the price target from $120 to $140.
February 01, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen maintains an Overweight rating on Novo Nordisk and raises the price target from $120 to $140.
The upgrade in the price target by a reputable analyst suggests a positive outlook on the company's future performance. This is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100